CARE Initiatives on Biosimilars.png

CARE (Community, Academic, Research, Education) believes in: optimization of current therapy, innovation with new treatments, and competition to help deliver savings and accessibility; considered in ways that deliver better healthcare solutions to Canadians. 

Biosimilars are a relevant topic to the Canadian landscape, given the recent introduction of several biosimilars as well as others expected to be available shortly. The CARE Faculty has been looking at the impact of biosimilars since 2015, given the significance of this topic across both chronic & acute specialties. The CARE faculty is interested in better understanding the impact of biosimilars and sharing this understanding with their contemporaries. 


CARE Primer on Biosimilars

These Congresses will take place in London, Calgary and Montreal in Fall 2017. The regional CARE Congresses on Biosimilars are an extension of the national meeting that was held on January 13th, 2017 in Toronto, ON.

Click here to read more.

CARE Guiding Principles on Biosimilars

Select CARE Faculty members have consolidated the following guiding principles based on the collective discussion from past CARE Education initiatives that explored the anticipated impact that the introduction of biosimilars will have in Canada.
Click here to read more.

 

CARE Congresses on Biosimilars - Fall 2017

These Congresses will take place in London, Calgary and Montreal in Fall 2017. The regional CARE Congresses on Biosimilars are an extension of the national meeting that was held on January 13th, 2017 in Toronto, ON.

Click here to read more.

CARE Perspectives on ECCO/CDDW 2017 

CARE Perspectives explores abstracts and research presented at both the 12th annual ECCO (European Crohn’s and Colitis Organisation) congress held in Barcelona, Spain (February 15-18, 2017) and the CDDW (Canadian Digestive Diseases Week) meeting in Banff, Alberta (March 3-6, 2017).
Click here to read more.

 

CARE Congress Report on Biosimilars

The CARE Congress Report on Biosimilars summarizes presentations given by a variety of stakeholders at the event. The Congress was chaired by Dr. John Kuruvilla from Princess Margaret Cancer Centre, and Dr. John Marshall from McMaster University. Dr. Hartmut Grasemann from SickKids Hospital facilitated the meeting.
Click here to read more.

 
 

CARE Needs Assessment on Biosimilars

Biosimilars are a reality in Canada. In an effort to promote a shared understanding of the range of issues, perspectives, and developments related to the use of biosimilars, the CARE Gastroenterology Faculty recently conducted a needs assessment. What follows is an overview of the key takeaways from the needs assessment, along with the response data.
Click here to read more.

 

CARE Perspectives on NOR-SWITCH Trial

CARE Gastroenterology Faculty lead, Dr. John Marshall (McMaster University), sat down with Dr. Brian Feagan (Professor of Medicine at the University of Western) to critically assess this study and discuss how the results should be interpreted and applied in Canadian practice. 
Click here to read more.

The CARE Congress on Biosimilars

On Friday, January 13th, the CARE™ Faculty specialists representing the fields of gastroenterology, hematology, oncology, respirology and rheumatology met to consider the integration of biosimilars into the Canadian healthcare system.
Click here to read more.
 

 

Gastro-Times: The Changing Landscape of Inflammatory Bowel Disease

Research continues to consider how to optimize the use of current biologic agents, drive innovation of new agents, and investigate how increased competition will affect practice, due to the introduction of biosimilars. This issue of Gastro-Times reviews these three key topics as they apply to the Canadian landscape. 
Click here to read more.